Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells

doi:10.1016/S0960-0760(97)00068-X

The Journal of Steroid Biochemistry and Molecular Biology

Volume 63, Issues 1–3, September–October 1997, Pages 29-36

https://doi.org/10.1016/S0960-0760(97)00068-X Get rights and content

Abstract

Stable aromatase-expressing MCF-7 and T-47D cell lines (i.e. MCF-7aro and T-47Daro) have been prepared by aromatase cDNA transfection and G418 (neomycin) selection. MCF-7aro was further subjected to a clonal purification. Aromatase activity in the transfected MCF-7 and T-47D cell lines was determined to be 73 ± 6 pmol/mg/h and 48 ± 4 pmol/mg/h, respectively. It is thought that these cell lines express aromatase in a stable manner, as demonstrated by a steady expression of the enzyme during culture in the absence of G418. The growth of these cells could be stimulated by androgens (1–10 nM) as demonstrated through a spheroid culture method. The androgen-stimulated growth could be suppressed by 4-hydroxyandrostenedione (4-OHA) (0.01–0.1 mM) or tamoxifen (50 nM-1 μM). In order to test the hypothesis that tumor aromatase can affect breast tumor growth in a paracrine manner, we have carried out cell culture experiments by co-culturing MCF-7 cells with either MCF-7aro or T-47Daro cells. Testosterone (1 nM) increased cell growth to a similar degree for MCF-7/MCF-7aro co-culture (0.75 × 10⁶ cells each type) as with MCF-7aro only (2- to 3-fold). In addition, the enzyme activities remained unchanged for MCF-7/MCF-7aro co-culture samples with and without androgen treatment, indicating that estrogen produced by transfected cells can also stimulate the growth of untransfected cells. The androgen response could be inhibited by an addition of 4-OHA (0.01–0.1 mM). For MCF-7/T-47Daro co-culture experiments, a clear induction of cell growth by androgen was observed, and the level of the increase was similar to that on T-47Daro only. However, for either culture with T-47D only or with MCF-7/T-47Daro co-culture, the aromatase activity was found to increase significantly after testosterone treatment. T-47Daro cells were not subjected to a clonal purification, and it is therefore thought that the androgen treatment may selectively stimulate the growth of high aromatase-expressing T-47Daro cells. These results indicate that estrogen synthesized by tumor aromatase can stimulate breast tumor growth in both an autocrine and a paracrine manner

References (25)

M.E. Lippman et al.
Autocrine and paracrine growth regulation of human breast cancer
Journal of Steroid Biochemistry
(1986)
H. Sasano et al.
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders
Human Pathology
(1994)
R.D. Koos et al.
Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction
Journal of Steroid Biochemistry and Molecular Biology
(1993)
C. Zhou et al.
Aromatase gene expression and its exon I usage in human breast tumors
Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction (RT-PCR)
Journal of Steroid Biochemistry and Molecular Biology
(1996)
W.R. Miller et al.
The importance of local synthesis of estrogen within the breast
Steroid
(1987)
J. Kitawaki et al.
Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors
Journal of Steroid Biochemistry and Molecular Biology
(1992)
S.J. Santner et al.
Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture
Journal of Steroid Biochemistry and Molecular Biology
(1993)
M.M. Bradford
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Analytical Biochemistry
(1976)
D. Zhou et al.
Aromatase gene is amplified in MCF-7 human breast cancer cells
Journal of Steroid Biochemistry and Molecular Biology
(1993)
M.J. Reed et al.
Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors
Journal of Steroid Biochemistry and Molecular Biology
(1993)

W.R. Miller et al.

Factors influencing aromatase activity in the breast

Journal of Steroid Biochemistry and Molecular Biology

(1993)

M.S. Sheikh et al.

Differential regulation of matrix Gla protein (MGP) gene expression by retinoic acid and estrogen in human breast carcinoma cells

Molecular and Cellular Endocrinology

(1993)

Cited by (89)

Design, synthesis, biological activity evaluation and structure-activity relationships of new steroidal aromatase inhibitors. The case of C-ring and 7β substituted steroids
2023, Bioorganic Chemistry
Citation Excerpt :
After this period, cells were cultured and incubated with testosterone (T) (Sigma-Aldrich Co., Saint Louis, USA), at 1 nM, the natural substrate of aromatase that is converted by this enzyme into estrogen, which induces cell proliferation. Thus, T was used as a cell proliferation induction agent, to better mimic the microenvironment of ER+ breast tumors [19,40]. After T, cells were also incubated with each compound.
In this work, new steroidal aromatase inhibitors (AIs) were designed, synthesized, and tested. In one approach, C-ring substituted steroids namely those functionalized at C-11 position with an α or β hydroxyl group or with a carbonyl group as well as C-9/C-11 steroidal olefins and epoxides were studied. It was found that the carbonyl group at C-11 is more beneficial for aromatase inhibition than the hydroxyl group, and that the C-ring epoxides were more potent than the C-ring olefins, leading to the discovery of a very strong AI, compound 7, with an IC₅₀ of 0.011 μM, better than Exemestane, the steroidal AI in clinical use, which presents an IC₅₀ of 0.050 μM. In another approach, we explored the biological activity of A-ring C-1/C-2 steroidal olefins and epoxides in relation to aromatase inhibition and compared it with the biological activity of C-ring C-9/C-11 steroidal olefins and epoxides. On the contrary to what was observed for the C-ring olefins and epoxides, the A-ring epoxides were less potent than A-ring olefins. Finally, the effect of 7β-methyl substitution on aromatase inhibition was compared with 7α-methyl substitution, showing that 7β-methyl is better than 7α-methyl substitution. Molecular modelling studies showed that the 7β-methyl on C-7 seems to protrude into the opening to the access channel of aromatase in comparison to the 7α-methyl. This comparison led to find the best steroidal AI (12a) of this work with IC₅₀ of 0.0058 μM. Compound 12a showed higher aromatase inhibition capacity than two of the three AIs currently in clinical use.
Anti-cancer properties of hydroethanolic extracts of Juniperus oxycedrus L. in breast cancer cells
2023, Journal of Herbal Medicine
Citation Excerpt :
Chromatographic and detection specifications were already reported elsewhere (El-Abid et al., 2019). MCF-7aro is a human ER+ breast cancer cell line that overexpresses aromatase, which is a good in vitro cell model to study this type of cancer (Sun et al., 1997; Zhou et al., 1990) and was kindly provided by Professor Shiuan Chen (Beckman Research Institute, City of Hope, Duarte, CA, USA). These cells grew with Eagles’ minimum essential medium (MEM) supplemented with 1% penicillin–streptomycin–amphotericin B, Earle’s salts and 1 mmol/L sodium pyruvate, 100 µg/mL G418, and 10% of heat-inactivated fetal bovine serum (FBS) (Gibco Invitrogen Co., Paisley, Scotland, UK).
Juniperus oxycedrus L. is a common Mediterranean tree that is frequently used in traditional medicine and European cuisine. Evidence suggests that Juniperus species may contain a large number of potentially anti-cancer molecules. Previously, the authors reported that essential oils of J. oxycedrus L. have anti-cancer properties in ER⁺ breast cancer cells. However, the potential therapeutic properties of hydroethanolic extracts are still unknown. Considering this and to highlight its anti-cancer properties, the in vitro effects of J. oxycedrus hydroethanolic extracts, of leaves and fruits, were investigated in ER⁺ breast cancer cells that overexpress aromatase (MCF-7aro).
The effect of extracts on cell viability, cell death, and cell cycle progression were analysed. In addition, the phytochemical composition and their antioxidant properties were evaluated.
Both extracts impaired breast cancer cell growth, by reducing cell viability, arresting cell cycle, and inducing mitochondrial apoptosis. Curiously, the presence of multinucleated cells and polyploidy in association with apoptosis suggested the involvement of mitotic catastrophe. Furthermore, both extracts had high antioxidant activity. Concerning the phytochemical analysis, it was demonstrated that both extracts were rich in flavonoids, which are known for their anti-cancer and antioxidant properties.
Therefore, this work emphasizes the impact of both hydroethanolic extracts of J. oxycedrus L. in ER⁺ breast cancer cells, suggesting their potential adjuvant therapeutic role for this type of cancer. Moreover, this study points out that the plant J. oxycedrus L. could be considered a new natural source of anti-cancer and antioxidant molecules with therapeutic potential.
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells
2021, Molecular and Cellular Endocrinology
Estrogen receptor-positive (ER⁺) breast carcinomas are the most common subtype, corresponding to 60% of the cases in premenopausal and 75% in postmenopausal women. The third-generation of aromatase inhibitors (AIs), the non-steroidal Anastrozole (Ana) and Letrozole (Let) and the steroidal Exemestane (Exe), are considered a first-line endocrine therapy for postmenopausal women. Despite their clinical success, the development of resistance is the major setback in clinical practice. Nevertheless, the lack of cross-resistance between AIs hints that these drugs may act through distinct mechanisms. Therefore, this work studied the different effects induced by AIs on biological processes, such as cell proliferation, death, autophagy and senescence. Moreover, their effects on the regulation of the hormonal environment were also explored. The non-steroidal AIs induce senescence, through increased YPEL3 expression, on aromatase-overexpressing breast cancer cells (MCF-7aro), whereas Exe promotes a cytoprotective autophagy, thus blocking senescence induction. In addition, in a hormone-enriched environment, the non-steroidal AIs prevent estrogen signaling, despite up-regulating the estrogen receptor alpha (ERα), while Exe down-regulates ERα and maintains its activation. In these conditions, all AIs up-regulate the androgen receptor (AR) which blocks EGR3 transcription in Exe-treated cells. On the other hand, in hormone-depleted conditions, a crosstalk between AR and ERα occurs, enhancing the estrogenic effects of Exe. This indicates that Exe modulates both ERα and AR, while Ana and Let act as pure AIs. Thus, this study highlights the potential clinical benefit of combining AR antagonists with Exe and discourages the sequential use of Exe as second-line therapy in postmenopausal breast cancer.
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action
2021, Toxicon
Estrogen receptor-positive (ER⁺) breast cancer is the most diagnosed subtype of breast cancer. Currently, aromatase inhibitors (AIs) are used as first-line treatment option in this type of tumors, however they cause several side effects, which is why new therapeutic approaches are demanding. The South American rattlesnake Crotalus durissus terrificus produces a venom enriched in several bioactive substances, like phospholipases A₂ (PLA₂). One of those is crotoxin, a β-neurotoxin, that has already been reported for its anti-cancer properties in different cancers. Recently, its clinical interest has emerged and, in fact, a clinical trial in patients with advanced cancer is underway. Considering this, in this work, we studied the biological mechanisms behind the anti-cancer effects of crotoxin B (CTX) in an ER⁺ aromatase-overexpressing breast cancer cell line (MCF-7aro cells). Results revealed that CTX impairs MCF-7aro cells growth, through a cell cycle arrest at G₂/M phase, inhibition of ERK1/2 pathway and by apoptosis through activation of caspase-8. In addition, it can be considered a safe natural compound as did not affect non-cancerous cells and only showed anti-growth effects in breast cancer cells. Therefore, this study represents an important landmark to better understand the effects and mechanisms of action of crotoxin in ER⁺ breast cancer.
Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER<sup>+</sup> breast cancer cells: Impact on aromatase and steroid receptors
2021, Journal of Steroid Biochemistry and Molecular Biology
Breast cancer is the leading cause of cancer-related death in women worldwide. In the last years, cannabinoids have gained attention in the clinical setting and clinical trials with cannabinoid-based preparations are underway. However, contradictory anti-tumour properties have also been reported. Thus, the elucidation of the molecular mechanisms behind their anti-tumour efficacy is crucial to better understand its therapeutic potential. Considering this, our work aims to clarify the molecular mechanisms underlying the anti-cancer properties of the endocannabinoid anandamide (AEA) and of the phytocannabinoids, cannabidiol (CBD) and Δ⁹-tetrahydrocannabinol (THC), in estrogen receptor-positive (ER⁺) breast cancer cells that overexpress aromatase (MCF-7aro). Their in vitro effects on cell proliferation, cell death and activity/expression of aromatase, ERα, ERβ and AR were investigated. Our results demonstrated that cannabinoids disrupted MCF-7aro cell cycle progression. Unlike AEA and THC that induced apoptosis, CBD triggered autophagy to promote apoptotic cell death. Interestingly, all cannabinoids reduced aromatase and ERα expression levels in cells. On the other hand, AEA and CBD not only exhibited high anti-aromatase activity but also induced up-regulation of ERβ. Therefore, all cannabinoids, albeit by different actions, target aromatase and ERs, impairing, in that way, the growth of ER⁺ breast cancer cells, which is dependent on estrogen signalling. As aromatase and ERs are key targets for ER⁺ breast cancer treatment, cannabinoids can be considered as potential and attractive therapeutic compounds for this type of cancer, being CBD the most promising one. Thus, from an in vitro perspective, this work may contribute to the growing mass of evidence of cannabinoids and cannabinoids-based medicines as potential anti-cancer drugs.
Discovery of a multi-target compound for estrogen receptor-positive (ER<sup>+</sup>) breast cancer: Involvement of aromatase and ERs
2021, Biochimie
Despite intense research, breast cancer remains the leading cause of cancer-related death in women worldwide, being estrogen receptor-positive (ER⁺) the most common subtype. Nowadays, aromatase inhibitors (AIs), the selective estrogen receptor modulator (SERM) tamoxifen and the selective estrogen receptor down-regulator (SERD) fulvestrant are used as therapeutic options for ER⁺ breast cancer, since they interfere directly with the production of estrogens and with the activation of estrogen-dependent signaling pathways. Despite the success of these treatments, the occurrence of resistance limits their clinical efficacy, demanding the development of novel therapies. Recently, multi-target compounds emerged as promising therapeutic strategies for ER⁺ breast cancer, as they can potentially modulate several important targets simultaneously. In line with this, in this work, the anti-cancer properties and multi-target action of 1,1-Bis(4-hydroxyphenyl)-2-phenylbut-1-ene, tamoxifen bisphenol (1,1-BHPE), were evaluated in an ER⁺ breast cancer cell model (MCF-7aro cells). Molecular docking analysis predicted that 1,1-BHPE was able to bind to aromatase, ERα and ERβ. In vitro studies showed that, although it did not present anti-aromatase activity, 1,1-BHPE reduced aromatase protein levels and interfered with ERα and ERβ signaling pathways, acting as an ERα antagonist and inducing ERβ up-regulation. Through these mechanisms, 1,1-BHPE was able to impair breast cancer growth and induce apoptosis. This represents an important therapeutic advantage because the main players responsible for estrogen production and signaling are modulated by a single compound. To the best of our knowledge, this is the first study describing the anti-cancer properties of 1,1-BHPE as a multi-target compound specific for ER⁺ breast cancer.

View all citing articles on Scopus

View full text

Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells

Abstract

Journal of Steroid Biochemistry

Human Pathology

Journal of Steroid Biochemistry and Molecular Biology

Journal of Steroid Biochemistry and Molecular Biology

Steroid

Journal of Steroid Biochemistry and Molecular Biology

Journal of Steroid Biochemistry and Molecular Biology

Analytical Biochemistry

Journal of Steroid Biochemistry and Molecular Biology

Journal of Steroid Biochemistry and Molecular Biology

Journal of Steroid Biochemistry and Molecular Biology

Molecular and Cellular Endocrinology